HER2 Support Group Forums - View Single Post - here we go again: How inexact ER status testing is!!!

Lani · 07-10-2007, 12:09 AM

: Am J Clin Pathol. 2007 Mar;127(3):356-65. Links
Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays.

Arihiro K, Umemura S, Kurosumi M, Moriya T, Oyama T, Yamashita H, Umekita Y, Komoike Y, Shimizu C, Fukushima H, Kajiwara H, Akiyama F.
Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan.
The aims of this study were to compare the quality of immunohistochemical assays of estrogen receptor (ER) and progesterone receptor (PR) and to compare the intermethod variability of assays from different manufacturers. immunohistochemical staining was entrusted to the following laboratories in Japan: Kyowa Medex, dealing with the products of BioGenex (Mishima, Shizuoka), DAKO Japan (Kyoto) and Ventana Japan (Yokohama). All slides were semiquantitatively evaluated according to the Allred score. Intermethod variability showed fair to moderate multirater kappa values for ER and PR (for total score, ER, kappa = 0.34; PR, kappa = 0.45). Another scoring system was also applied in which, irrespective of the intensity of nuclear staining, the proportion of cells stained in each specimen was recorded as 0; less than 1%; 1% or more and less than 10%; or 10% or more. Intermethod variability showed substantial multirater kappa values for ER and PR (according to percentage of positive cells, ER, kappa = 0.67; PR, kappa = 0.72). Concerning intermethod consistency, the scoring system based on the percentage of positive cells was advantageous over other scoring systems.
PMID: 17276950 [PubMed - indexed for MEDLINE]

Related Links
Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. [Virchows Arch. 2002]
The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. [Breast Cancer. 2007]
Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer. [Anticancer Res. 1996]
Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. [J Clin Pathol. 2000]
Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. [Anticancer Res. 1997]
See all Related Articles...

07-10-2007, 12:09 AM	#6
Lani Senior Member Join Date: Mar 2006 Posts: 4,780	more...... : Am J Clin Pathol. 2007 Mar;127(3):356-65. Links Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays. Arihiro K, Umemura S, Kurosumi M, Moriya T, Oyama T, Yamashita H, Umekita Y, Komoike Y, Shimizu C, Fukushima H, Kajiwara H, Akiyama F. Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan. The aims of this study were to compare the quality of immunohistochemical assays of estrogen receptor (ER) and progesterone receptor (PR) and to compare the intermethod variability of assays from different manufacturers. immunohistochemical staining was entrusted to the following laboratories in Japan: Kyowa Medex, dealing with the products of BioGenex (Mishima, Shizuoka), DAKO Japan (Kyoto) and Ventana Japan (Yokohama). All slides were semiquantitatively evaluated according to the Allred score. Intermethod variability showed fair to moderate multirater kappa values for ER and PR (for total score, ER, kappa = 0.34; PR, kappa = 0.45). Another scoring system was also applied in which, irrespective of the intensity of nuclear staining, the proportion of cells stained in each specimen was recorded as 0; less than 1%; 1% or more and less than 10%; or 10% or more. Intermethod variability showed substantial multirater kappa values for ER and PR (according to percentage of positive cells, ER, kappa = 0.67; PR, kappa = 0.72). Concerning intermethod consistency, the scoring system based on the percentage of positive cells was advantageous over other scoring systems. PMID: 17276950 [PubMed - indexed for MEDLINE] Related Links Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. [Virchows Arch. 2002] The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. [Breast Cancer. 2007] Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer. [Anticancer Res. 1996] Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. [J Clin Pathol. 2000] Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. [Anticancer Res. 1997] See all Related Articles...